Lakefront Biotherapeutics NV (LKFT) News & EventsLKFTNews & EventsLakefront Biotherapeutics NV

Lakefront Biotherapeutic Receives FDA Orphan Drug Designation

Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the FDA for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig is being developed by Lakefront in collaboration with Gilead (GILD). Ongoing clinical trials in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.